Skip to content

Evaluation of the effect of vitamin D3 supplementation in doses of 1000 and 3000 IU / day on hyperglycemic control, wound healing,wound infection and sepsis incidence and length of stay in hospital in burn patients

Evaluation of the effect of vitamin D3 supplementation in doses of 1000 and 3000 IU / day on hyperglycemic control, wound healing,wound infection and sepsis incidence and length of stay in hospital in burn patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200420047141N1
Enrollment
54
Registered
2020-04-24
Start date
2020-04-23
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn patients. Burn of second degree, body region unspecified, Burn of third degree, body region unspecified

Interventions

Intervention 1: Intervention group:The first group receives a dose of 1000IU vitamin D from Flexan on a daily basis and orally from the time of admission until discharge from the hospital. Interventio

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age group 50_18 years Burns 50-20% Second and third degree burns At least two weeks in the hospital according to the doctor's prognosis Satisfaction of the individual Absence of chronic diseases such as diabetes and high blood pressure and chronic kidney disease No supplement with Vit D in the last 6 months Lack of disorders such as hypoparathyroidism, hyperthyroidism, tumors and bone disease Not receiving sex hormones to treat osteoporosis Patient awareness and ability to answer questionnaire questions Able to receive oral vitamin

Exclusion criteria

Exclusion criteria: Diagnosis of the relevant physician and discretion to discontinue the supplement due to clinical problems created in the patient The patient's reluctance to continue studying Reduce awareness and ability to answer questionnaire questions The patient's death

Design outcomes

Primary

MeasureTime frame
Hyperglycemic control. Timepoint: At least twice a week. Method of measurement: Blood sampling in fasting mode.;Wound healing. Timepoint: Before the start of the intervention, 7 days and 14 days after the intervention. Method of measurement: Bates-jensenWound assessment tool.;Infection of the wound and sepsis. Timepoint: On the fifth day of hospitalization. Method of measurement: Biopsy of wound depth and blood culture.;The length of hospitalisation. Timepoint: From admission to discharge. Method of measurement: Count the number hospitalisation days.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElaheh Ghadimi

Ahvaz University of Medical Sciences

ghadimi.elaheh1996@gmail.com+98 61 3337 1272

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026